Patents Assigned to TVAX BIOMEDICAL I, LLC
  • Methods for combining adoptive T cell therapy with oncolytic virus adjunct therapy
    Patent number: 11633442
    Abstract: The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: April 25, 2023
    Assignee: TVAX BIOMEDICAL I, LLC
    Inventors: Gary Wood, Jochen Harald Stritzker